Skip to main content

Market Overview

Axonics Acquires Urethral Bulking Agent For $200M

  • Axonics Modulation Technologies Inc (NASDAQ: AXNXhas acquired UK-based Contura and its lead product Bulkamid, a urethral bulking agent used to treat female stress urinary incontinence.
  • The transaction includes a total consideration of $200 million in cash and stock, along with a potential future milestone of $35 million.
  • Bulkamid is a homogenous non-particulate hydrogel injected into the urethral wall in a minimally invasive office or outpatient facility procedure for restoring the urethra’s natural closing pressure.
  • The hydrogel secured CE Mark approval in 2003 and the FDA approval last year.
  • Price Action: AXNX shares are 1.34% higher at $51.50 in the premarket session on the last check Friday.

Related Articles (AXNX)

View Comments and Join the Discussion!

Posted-In: urinary tract infectionsBiotech M&A News Health Care FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at